Issue 1877: June 3, 2026

Vaccinate Your Family (VYF) launched a free minicourse, Measles: What Everyone Needs to Know. In this course, you will follow Elena as she learns about measles (e.g., how it is spread, who is most at risk) and how the vaccine protects children, teens, and adults. You’ll also learn how to address common myths and have supportive conversations about measles prevention.

Visit VYF University to see the minicourses, each of which is free and self-paced.

Enroll in the course.

---

Medscape Education released a curriculum, Targeting Viral Hepatitis: A Road Map for Providers, with several activities featuring expert perspectives on preventing and managing viral hepatitis. 

The activities include:

• Closing the Loop: Smarter Workflows for Hepatitis Screening and Prevention: How can clinicians engage patients in discussions about viral hepatitis? (30 min)
• Are Your Workflows Working? Embedding Hepatitis Screening and Vaccination into Routine Care: Protect your patients against viral hepatitis. (15 min)
• How Do You Stack Up? Case Challenges in Guideline-Based Management of Viral Hepatitis: Assess your ability to screen for hepatitis B and hepatitis C. (60 min)

The curriculum titled "Are Your Workflows Working? Embedding Hepatitis Screening and Vaccination into Routine Care" was codeveloped and moderated by Immunize.org’s L.J Tan, PhD. A description of the curriculum appears below.

Despite advances in effective therapies, viral hepatitis rates continue to increase, especially among certain communities, identified as priority health populations. These populations include people who inject drugs (PWID), Asians and Pacific Islanders, American Indians/Alaska Natives, and non-Hispanic Black persons. Furthermore, systemic barriers, stigma, and discrimination impede access to health services for people at increased risk for viral hepatitis. These factors contribute to missed/late diagnosis, onward transmission, costly tertiary care, and reduced quality of life. This collection of CME-certified activities provides strategies to overcome barriers and deliver equitable care to further the achievement of hepatitis elimination goals in the United States and worldwide.

To earn CME, ABIM MOC, or CE credit, please click here.

Immunize.org's www.Give2MenACWY.org website promotes the importance of adolescent vaccination, including the recommended MenACWY vaccine booster dose at age 16. Many teens are behind on vaccines, so vaccine outreach is more important than ever.

If you are looking for tools to explain meningococcal vaccine recommendations and assist in improving adolescent coverage for all recommended vaccines, view this site. Check out the many helpful tools from Immunize.org, CDC, and other organizations.

  

The website is divided into five easy-to-access sections:

• Vaccinate Teens: teen vaccination schedules and tips for improving vaccination rates
• Give 2 Doses: tools to help improve second dose coverage of MenACWY vaccine
• 16-Year-Old Visit: resources to help providers and patients remember the important vaccines recommended for 16-year-olds
• Tools for Providers: tools to explain meningococcal ACWY vaccine recommendations and improve coverage for all adolescent vaccines
• Resources: links to print materials, organizations involved in adolescent vaccination, personal stories about the importance of vaccination, and other resources of interest

The site also categorizes materials according to whether they are primarily of interest to providers, to adolescents, or to parents.

Visit Give2MenACWY.org and enjoy browsing (and deploying) its bountiful resources.

Related Links 

• MenACWY: You're Not Done If You Give Just One: Give 2 Doses to Strengthen Protection
• Recommending MenACWY: What to Say and How to Say It
• Top 10 Ways to Improve Adolescent Immunization Rates 
• Developing an Immunization Culture in Your Office 
• Know Your Rates: Measuring Immunization Success in Your Practice
• Immunize.org: You're 16: We Recommend These Vaccines for You
• Dear Colleague Letter: 16-Year-Old Patients: Make Sure They Receive Their Annual Well Visit and Vaccinations, signed by six medical societies
• Immunize.org: Ask the Experts: Meningococcal ACWY 
• CDC: ACIP Meningococcal Vaccine Recommendations
• CDC: Vaccination Coverage Among Adolescents Aged 13–17 Years—National Immunization Survey–Teen, United States, 2024

---

---

In its April 17 issue, Pediatrics published Hepatitis B Vaccination at Birth: Safety, Effectiveness, and Public Health Benefit. The comprehensive evidence review found strong support for the safety and effectiveness of the HepB birth dose and no benefit to delaying HepB vaccination, so withholding the HepB birth dose only risks reversing a decades-long 99% reduction in pediatric hepatitis B virus infections. A portion of the video abstract appears below.



We conducted a comprehensive review of the evidence on the safety, immunogenicity, efficacy, and effectiveness of the birth dose and a delayed first dose, and of the potential role of serology for clinical decision-making. We analyzed studies of the epidemiology of HBV infection, clinical trials, systematic reviews, vaccine safety from surveillance and clinical studies, and the potential impact of revised guidelines on individual and public health. We synthesized the history of ACIP recommendations and resulting trends in HBV incidence. The review found strong evidence for the safety and effectiveness of the birth dose, and no improvement in safety or effectiveness with a delayed first dose. We found no evidence to support the use of postvaccination serology. Infant vaccination has resulted in a 99% reduction in pediatric HBV infections; we found no evidence to support a change in vaccine recommendations but identified potential health consequences.

In its May 20 issue, JAMA Network Open published Live Attenuated Measles-Mumps-Rubella and Varicella Vaccinations and Multiple Sclerosis Activity. A portion of the abstract appears below.

In this cohort study of nonimmunosuppressed people with MS [multiple sclerosis], vaccination with live attenuated MMR or varicella vaccine was not associated with increased risk of postvaccination relapse. The results support the administration of these vaccines when indicated and may help reassure clinicians and patients, reducing vaccine hesitancy.

---

At the 79th World Health Assembly, held May 18–23, more than 70 member states and global health partners reaffirmed their commitment to the Immunization Agenda 2030 (IA2030), recognizing vaccines as one of the most powerful, cost-effective, and equitable public health tools available. Delegates stressed that strong immunization programs are the foundation of outbreak preparedness, resilient health systems, and long-term health security.

At the same time, leaders warned that progress toward IA2030 targets remains off track. Rising measles outbreaks, declining routine immunization coverage in several regions, and growing inequalities in vaccine access were cited as urgent concerns. Delegates called for renewed focus on reaching "zero-dose" children—those who never received any vaccine—particularly in fragile, conflict-affected, and hard-to-reach areas. Misinformation and declining public trust in vaccines were also highlighted as serious threats, with countries calling for stronger community engagement and health communication strategies to counter misinformation.

The World Health Organization committed to advancing the recommendations of the IA2030 Mid-Term Review and strengthening collaboration with Gavi, the Vaccine Alliance; United Nations International Children’s Emergency Fund (UNICEF); and other partners. Member states emphasized that achieving IA2030 goals will require not only scientific innovation but also sustained financing, domestic investment, political commitment, and international solidarity.

---

---

Vaccinators and vaccine recipients face unprecedented challenges as vaccination recommendations of federal, state, and healthcare professional organizations proliferate and diverge. The Summit Adult Vaccination Recommendations Review (SAVRR) Council is an independently funded committee of the National Adult and Influenza Immunization Summit (NAIIS), known as “the Summit,” dedicated to supporting implementation of evidence-based vaccination recommendations in this new environment.

The SAVRR Council will host its first public webinar online 2:00–3:00 p.m. (ET) on June 9.

The SAVRR Council is composed of a broad range of voting member organizations and observers whose representatives were screened by their organizations for conflicts of interest. All participating organizations and their representatives are listed at the SAVRR web page. Vaccine manufacturers and trade organizations do not participate in SAVRR meetings and do not provide any financial support for the Council. The objectives of the SAVRR Council are twofold:

1. Serve as a forum to provide practical, diverse stakeholder feedback to organizations making vaccination recommendations
2. Support clinical implementation of evidence-based vaccination recommendations by identifying challenges to implementation and recommending strategies to increase affordable access and vaccine use

Working meetings of the SAVRR Council occur monthly, with quarterly public meetings planned. The initial 1-hour public webinar will describe its purpose and the procedures that guide its work. In addition, it will review the SAVRR Council’s preliminary recommendations for effective implementation of fall respiratory vaccination recommendations. The meeting will conclude with discussion of plans for future open meetings and opportunities for ongoing engagement. Immunize.org administers and serves as the fiscal agent for the NAIIS and the SAVRR Council.

Register for the meeting.

Related Links

• NAIIS main page
• SAVRR Council main page
• SAVRR Council Member Organizations (PDF)

---

To learn simple tips and tricks for using our websites efficiently, please register for our next set of Website Office Hours on Wednesday, June 10, at 4:00 p.m. (ET) or Thursday, June 11, at 12:00 p.m. (ET). The same content will be covered in both sessions.

We will open each 30-minute session with a short, live demonstration on navigating our Vaccine Confidence & Addressing Concerns website section. You can submit questions when you register or live on Zoom during the session.

Register today for Immunize.org Website Office Hours (content is the same for both):

• Wednesday, June 10, at 4:00 p.m. (ET)
• Thursday, June 11, at 12:00 p.m. (ET)

The archive of previous Website Office Hours content is posted at Immunize.org’s "Webinars & Videos" page.

Mark your calendar for future Immunize.org Website Office Hours.

---

For more upcoming events, visit our Calendar of Events.